The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease
Open accessAbstract
BACKGROUND: Myeloablative allogeneic hematopoietic stem-cell transplantation is curative in children with sickle cell disease, but in adults the procedure is unduly toxic. Graft rejection and graft-versus-host disease (GVHD) are additional barriers to its success. We performed nonmyeloablative stem-cell transplantation in adults with sickle cell disease. METHODS: Ten adults (age range, 16 to 45 years) with severe sickle cell disease underwent nonmyeloablative transplantation with CD34+ peripheral-blood stem cells, mobilized by granulocyte colony-stimulating factor (G-CSF), which were obtained from HLA-matched siblings. The patients received 300 cGy of total-body irradiation plus alemtuzumab before transplantation, and sirolimus was administered afterward. RESULTS: All 10 patients were alive at a median follow-up of 30 months after transplantation (range, 15 to 54). Nine patients had long-term, stable donor lymphohematopoietic engraftment at levels that sufficed to reverse the sickle cell disease phenotype. Mean (+/-SE) donor-recipient chimerism for T cells (CD3+) and myeloid cells (CD14+15+) was 53.3+/-8.6% and 83.3+/-10.3%, respectively, in the nine patients whose grafts were successful. Hemoglobin values before transplantation and at the last follow-up assessment were 9.0+/-0.3 and 12.6+/-0.5 g per deciliter, respectively. Serious adverse events included the narcotic-withdrawal syndrome and sirolimus-associated pneumonitis and arthralgia. Neither acute nor chronic GVHD developed in any patient. CONCLUSIONS: A protocol for nonmyeloablative allogeneic hematopoietic stem-cell transplantation that includes total-body irradiation and treatment with alemtuzumab and sirolimus can achieve stable, mixed donor-recipient chimerism and reverse the sickle cell phenotype. (ClinicalTrials.gov number, NCT00061568.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sickle Cell Anemia, a Molecular Disease
Pauling, L., Itano, H. A., Singer, S. J., & Wells, I. C. (1949) · Science · doi:10.1126/science.110.2865.543 · Cited by 2,319
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationChilds, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, E. J., Tisdale, J., Dunbar, C., Linehan, W. M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009143431101 · Cited by 998
Self-citationINGRAM, V. M. (1957) · Nature · doi:10.1038/180326a0 · Cited by 978
Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 931
Battaglia, M., Stabilini, A., Migliavacca, B., Horejs-Hoeck, J., Kaupper, T., & Roncarolo, M.-G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8338 · Cited by 736
Bone Marrow Transplantation for Sickle Cell Disease
Walters, M. C., Patience, M., Leisenring, W., Eckman, J. R., Scott, J. P., Mentzer, W. C., Davies, S. C., Ohene-Frempong, K., Bernaudin, F., Matthews, D. C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608083350601 · Cited by 627
Outcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients
Powars, D. R., Chan, L. S., Hiti, A., Ramicone, E., & Johnson, C. (2005) · Medicine · doi:10.1097/01.md.0000189089.45003.52 · Cited by 558
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease
Bernaudin, F., Socie, G., Kuentz, M., Chevret, S., Duval, M., Bertrand, Y., Vannier, J.-P., Yakouben, K., Thuret, I., Bordigoni, P., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079665 · Cited by 515
Kottaridis, P. D., Milligan, D. W., Chopra, R., Chakraverty, R. K., Chakrabarti, S., Robinson, S., Peggs, K., Verfuerth, S., Pettengell, R., Marsh, J. C. W., et al. (2000) · Blood · doi:10.1182/blood.v96.7.2419 · Cited by 504
Survival of children with sickle cell disease
Quinn, C. T., Rogers, Z. R., & Buchanan, G. R. (2004) · Blood · doi:10.1182/blood-2003-11-3758 · Cited by 377
Chronic Renal Failure in Sickle Cell Disease: Risk Factors, Clinical Course, and Mortality
Powars, D. R., Elliott-Mills, D. D., Chan, L., Niland, J., Hiti, A. L., Opas, L. M., & Johnson, C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-8-614 · Cited by 360
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia
Walters, M. C., Patience, M., Leisenring, W., Rogers, Z. R., Aquino, V. M., Buchanan, G. R., Roberts, I. A. G., Yeager, A. M., Hsu, L., Adamkiewicz, T., et al. (2001) · Biology of Blood and Marrow Transplantation · doi:10.1053/bbmt.2001.v7.pm11787529 · Cited by 324
Powell, J. D., Lerner, C. G., & Schwartz, R. H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2775 · Cited by 289
Self-citationFraser, C. J., Bhatia, S., Ness, K., Carter, A., Francisco, L., Arora, M., Parker, P., Forman, S., Weisdorf, D., Gurney, J. G., et al. (2006) · Blood · doi:10.1182/blood-2006-02-003954 · Cited by 281
Duration of immunosuppressive treatment for chronic graft-versus-host disease
Stewart, B. L., Storer, B., Storek, J., Deeg, H. J., Storb, R., Hansen, J. A., Appelbaum, F. R., Carpenter, P. A., Sanders, J. E., Kiem, H.-P., et al. (2004) · Blood · doi:10.1182/blood-2004-01-0200 · Cited by 281
Anthi, A., Machado, R. F., Jison, M. L., Taveira-DaSilva, A. M., Rubin, L. J., Hunter, L., Hunter, C. J., Coles, W., Nichols, J., Avila, N. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200610-1498oc · Cited by 270
Iannone, R., Casella, J. F., Fuchs, E. J., Chen, A. R., Jones, R. J., Woolfrey, A., Amylon, M., Sullivan, K. M., Storb, R. F., & Walters, M. C. (2003) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(03)00192-7 · Cited by 269
Vermylen, C., Cornu, G., Ferster, A., Brichard, B., Ninane, J., Ferrant, A., Zenebergh, A., Maes, P., Dhooge, C., Benoit, Y., et al. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701291 · Cited by 260
Effect of Campath-1H antibody on human hematopoietic progenitors in vitro
Gilleece, M., & Dexter, T. (1993) · Blood · doi:10.1182/blood.v82.3.807.807 · Cited by 217
Wierenga, K. J., Hambleton, I. R., Lewis, N. A., & Unit, S. C. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04132-5 · Cited by 209
Morris, E. C., Rebello, P., Thomson, K. J., Peggs, K. S., Kyriakou, C., Goldstone, A. H., Mackinnon, S., & Hale, G. (2003) · Blood · doi:10.1182/blood-2002-09-2687 · Cited by 194
Cutler, C., Li, S., Ho, V. T., Koreth, J., Alyea, E., Soiffer, R. J., & Antin, J. H. (2007) · Blood · doi:10.1182/blood-2006-09-046219 · Cited by 187
Coenen, J. J. A., Koenen, H. J. P. M., van Rijssen, E., Kasran, A., Boon, L., Hilbrands, L. B., & Joosten, I. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705628 · Cited by 164
Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing
Nollet, F., Billiet, J., Selleslag, D., & Criel, A. M. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703162 · Cited by 121
Pharmacokinetics of CAMPATH-1H in BMT patients
Rebello, P., Cwynarski, K., Varughese, M., Eades, A., Apperley, J. F., & Hale, G. (2001) · Cytotherapy · doi:10.1080/146532401317070899 · Cited by 118
Srinivasan, R., Takahashi, Y., McCoy, J. P., Espinoza‐Delgado, I., Dorrance, C., Igarashi, T., Lundqvist, A., Barrett, A. J., Young, N. S., Geller, N. L., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06019.x · Cited by 116
Self-citationBenefit-Risk Assessment of Sirolimus in Renal Transplantation
Kuypers, D. R. J. (2005) · Drug Safety · doi:10.2165/00002018-200528020-00006 · Cited by 101
Kang, E. M., Areman, E. M., David‐Ocampo, V., Fitzhugh, C. D., Link, M. E., Read, E. J., Leitman, S. F., Rodgers, G. P., & Tisdale, J. F. (2002) · Blood · doi:10.1182/blood.v99.3.850 · Cited by 77
Self-citationDissecting the mechanism of T-cell anergy with immunophilin ligands.
Powell, J. D., & Zheng, Y. (2006) · PubMed · Cited by 34
Self-citationLow-Dose Radiation Plus Rapamycin Promotes Long-Term Bone Marrow Chimerism
Powell, J. D., Fitzhugh, C. D., Kang, E. M., Hsieh, M., Schwartz, R. H., & Tisdale, J. F. (2005) · Transplantation · doi:10.1097/01.tp.0000185299.72295.90 · Cited by 32
Self-citation
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members
Yawn, B. P., Buchanan, G. R., Afenyi-Annan, A. N., Ballas, S. K., Hassell, K. L., James, A. H., Jordan, L., Lanzkron, S. M., Lottenberg, R., Savage, W. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.10517 · Cited by 1,599
Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836
Self-citationGluckman, E., Cappelli, B., Bernaudin, F., Labopin, M., Volt, F., Carreras, J., Pinto Simões, B., Ferster, A., Dupont, S., de la Fuente, J., et al. (2017) · Blood · doi:10.1182/blood-2016-10-745711 · Cited by 495
Metadata
- Authors
- Hsieh, M. M., Kang, E. M., Fitzhugh, C. D., Link, M. B., Bolan, C. D., Kurlander, R., Childs, R. W., Rodgers, G. P., Powell, J. D., & Tisdale, J. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-10
- Volume
- 361
- Issue
- 24
- Pages
- 2309-2317
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2065697585
- Cited by
- 455
- References
- 31
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.